Cargando…

Stepwise management of COPD: What is next after bronchodilation?

Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) in combination is currently the mainstay of treatment for chronic obstructive pulmonary disease (COPD). Treatment guidelines recommend the addition of inhaled corticosteroids (ICS) to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miravitlles, Marc, Matsunaga, Kazuto, Dreher, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631322/ https://www.ncbi.nlm.nih.gov/pubmed/37936381 http://dx.doi.org/10.1177/17534666231208630

Ejemplares similares

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Time To Revise COPD Treatment Algorithm
por: Matsunaga, Kazuto, et al.
Publicado: (2019)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD
por: Miravitlles, Marc
Publicado: (2007)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives
por: Rhee, Chin Kook, et al.
Publicado: (2019)

COPD symptoms in the morning: impact, evaluation and management
por: Roche, Nicolas, et al.
Publicado: (2013)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients
por: Minakata, Yoshiaki, et al.
Publicado: (2020)

What have we learned from observational studies and clinical trials of mild to moderate COPD?
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

COPD heterogeneity: implications for management
por: Barrecheguren, Miriam, et al.
Publicado: (2016)

Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT(®) studies
por: Miravitlles, Marc, et al.
Publicado: (2009)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
por: Matera, Maria Gabriella, et al.
Publicado: (2015)

Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
por: Price, David, et al.
Publicado: (2016)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
por: Donohue, James F, et al.
Publicado: (2019)

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
por: Corrao, Salvatore, et al.
Publicado: (2017)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

COPD management: role of symptom assessment in routine clinical practice
por: van der Molen, Thys, et al.
Publicado: (2013)

Understanding the impact of symptoms on the burden of COPD
por: Miravitlles, Marc, et al.
Publicado: (2017)

Is it Reasonable to Start Bronchodilator Treatment Before Confirming the Diagnosis of COPD?
por: Figueira-Gonçalves, Juan Marco, et al.
Publicado: (2023)

Airway wall thickness is increased in COPD patients with bronchodilator responsiveness
por: Kim, Victor, et al.
Publicado: (2014)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
por: Pascoe, Steven, et al.
Publicado: (2016)

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity
por: Barjaktarevic, Igor, et al.
Publicado: (2018)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial
por: Ramírez-Venegas, Alejandra, et al.
Publicado: (2019)

Chronic bronchial infection in COPD. Is there an infective phenotype?
por: Matkovic, Zinka, et al.
Publicado: (2013)

Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
por: Rossi, Andrea, et al.
Publicado: (2015)

Spirometry and Bronchodilator Test
por: Sim, Yun Su, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lqq2qk8dknfrajfsg8v71klpir